Tamoxifen ( DrugBank: Tamoxifen )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症3
113筋ジストロフィー7
227オスラー病1

2. 筋萎縮性側索硬化症


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02166944
(ClinicalTrials.gov)
April 20149/6/2014Tamoxifen Treatment in Patients With Motor Neuron DiseaseThe Study of Tamoxifen Treatment in Patients With Motor Neuron DiseaseAmyotrophic Lateral Sclerosis;ALS Functional Ration Scale;TAR-DNA-binding Protein-43;Tamoxifen;mTORDrug: tamoxifen 40 mg daily for one yearTaipei Medical University Shuang Ho HospitalNULLCompleted20 Years80 YearsAll20Phase 1/Phase 2Taiwan
2NCT01257581
(ClinicalTrials.gov)
March 20118/12/2010Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)Phase 2 Selection Trial of High Dosage Creatine and Two Dosages of Tamoxifen in Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: creatine;Drug: tamoxifenNazem AtassiALS Therapy Alliance;State University of New York - Upstate Medical UniversityCompleted18 YearsN/AAll60Phase 2United States
3NCT00214110
(ClinicalTrials.gov)
January 200113/9/2005Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]Phase 2 Randomized Single-blind Escalating Dose Response Clinical Trial of Tamoxifen Therapy on Mean Percent Predicted Isometric Strength in Amyotrophic Lateral Sclerosis [ALS]Amyotrophic Lateral Sclerosis (ALS)Drug: TamoxifenUniversity of Wisconsin, MadisonNULLCompleted18 Years90 YearsBoth100Phase 2United States

113. 筋ジストロフィー


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-004554-42-FR
(EUCTR)
26/03/202017/08/2018The study examines boys suffering from Duchenne muscular dystrophy. We are carrying out this study to examine the effect and tolerance of Tamoxifen in this disease.Tamoxifen in Duchenne muscular dystrophy - TAMDMDA multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial Duchenne muscular dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Tamoxifen 20mg Hexal® Filmtabletten
INN or Proposed INN: Tamoxifen
Other descriptive name: TAMOXIFEN CITRATE
University of Basel Children's Hospital, Division of NeuropediatricsNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
100Phase 3France;Belgium;Spain;Turkey;Netherlands;Germany;United Kingdom;Switzerland
2EUCTR2017-004554-42-GB
(EUCTR)
29/01/201903/08/2018The study examines boys suffering from Duchenne muscular dystrophy. We are carrying out this study to examine the effect and tolerance of Tamoxifen in this disease.Tamoxifen in Duchenne muscular dystrophy - TAMDMDA multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trialTamoxifen in Duchenne muscular dystrophy: A 48-week open labelextension of a multicentre, randomised, double-blind, placebo-controlled,phase 3 safety and efficacy trial Duchenne muscular dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Tamoxifen 20mg Hexal® Filmtabletten
INN or Proposed INN: Tamoxifen
Other descriptive name: TAMOXIFEN CITRATE
University of Basel Children's Hospital, Division of NeuropediatricsNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
100Phase 3France;Belgium;Spain;Netherlands;Germany;Switzerland;United Kingdom
3EUCTR2017-004554-42-ES
(EUCTR)
22/01/201917/09/2018The study examines boys suffering from Duchenne muscular dystrophy. We are carrying out this study to examine the effect and tolerance of Tamoxifen in this disease. Tamoxifen in Duchenne muscular dystrophy - TAMDMD A multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial Duchenne muscular dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: TAMOX
INN or Proposed INN: Tamoxifen
Other descriptive name: TAMOXIFEN CITRATE
University of Basel Children's Hospital, Division of NeuropediatricsNULLAuthorised-recruitment may be ongoing or finished Female: no
Male: yes
100 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noFrance;Belgium;Spain;Turkey;Netherlands;Germany;United Kingdom;Switzerland
4EUCTR2017-004554-42-NL
(EUCTR)
16/01/201902/10/2018The study examines boys suffering from Duchenne muscular dystrophy. We are carrying out this study to examine the effect and tolerance of Tamoxifen in this disease.Tamoxifen in Duchenne muscular dystrophy - TAMDMDA multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial Duchenne muscular dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: TAMOXIFEN
INN or Proposed INN: Tamoxifen
Other descriptive name: TAMOXIFEN CITRATE
University of Basel Children's Hospital, Division of NeuropediatricsNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
100Phase 3France;Belgium;Spain;Turkey;Germany;Netherlands;United Kingdom;Switzerland
5NCT03354039
(ClinicalTrials.gov)
June 12, 201810/10/2017Tamoxifen in Duchenne Muscular DystrophyTamoxifen in Duchenne Muscular Dystrophy: A Multicenter, Randomised, Double-blind, Placebo-controlled, Phase 3 Safety and Efficacy 48-week TrialDuchenne Muscular DystrophyDrug: Tamoxifen;Drug: Matching placeboUniversity Hospital, Basel, SwitzerlandNULLCompleted78 Months16 YearsMale93Phase 3France;Germany;Netherlands;Spain;Switzerland;United Kingdom
6EUCTR2017-004554-42-BE
(EUCTR)
30/04/2019The study examines boys suffering from Duchenne muscular dystrophy. We are carrying out this study to examine the effect and tolerance of Tamoxifen in this disease.Tamoxifen in Duchenne muscular dystrophy:A multicenter, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trialTamoxifen in Duchenne muscular dystrophy: A 48-week open label extension of a multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy trial Duchenne muscular dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Tamoxifen 20mg Hexal® Filmtabletten
INN or Proposed INN: Tamoxifen
Other descriptive name: TAMOXIFEN CITRATE
University of Basel Children's Hospital, Division of NeuropediatricsNULLNAFemale: no
Male: yes
100Phase 3France;Spain;Belgium;Turkey;Netherlands;Germany;United Kingdom;Switzerland
7EUCTR2017-004554-42-DE
(EUCTR)
27/07/2018The study examines boys suffering from Duchenne muscular dystrophy. We are carrying out this study to examine the effect and tolerance of Tamoxifen in this disease. Tamoxifen in Duchenne muscular dystrophy: A multicenter, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial Tamoxifen in Duchenne muscular dystrophy: A 48-week open label extension of a multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy trial Duchenne muscular dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Tamoxifen 20mg Hexal® Filmtabletten
INN or Proposed INN: Tamoxifen
Other descriptive name: TAMOXIFEN CITRATE
University of Basel Children's Hospital, Division of NeuropediatricsNULLNA Female: no
Male: yes
100 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noFrance;Belgium;Spain;Turkey;Netherlands;Germany;United Kingdom;Switzerland

227. オスラー病


臨床試験数 : 56 薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00375622
(ClinicalTrials.gov)
February 200512/9/2006Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical TrialHereditary Hemorrhagic TelangiectasiaDrug: TamoxifenRabin Medical CenterNULLCompleted18 YearsN/ABoth60Phase 2Israel